leupeptin has been researched along with primaquine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morton, PA; Owensby, DA; Schwartz, AL; Underhill, DM | 1 |
| Loss, GE; Sant, AJ | 1 |
| Ostrand-Rosenberg, S; Qi, L | 1 |
3 other study(ies) available for leupeptin and primaquine
| Article | Year |
|---|---|
Endocytosis and lysosomal delivery of tissue plasminogen activator-inhibitor 1 complexes in Hep G2 cells.
Topics: Ammonium Chloride; beta-N-Acetylhexosaminidases; Carcinoma, Hepatocellular; Chloroquine; Endocytosis; Humans; Kinetics; Leupeptins; Liver Neoplasms; Lysosomes; Pepstatins; Plasminogen Activator Inhibitor 1; Primaquine; Recombinant Proteins; Subcellular Fractions; Tissue Plasminogen Activator; Tumor Cells, Cultured | 1992 |
Invariant chain retains MHC class II molecules in the endocytic pathway.
Topics: Ammonium Chloride; Animals; Antigens, Differentiation, B-Lymphocyte; Cell Line; Chloroquine; Endocytosis; Histocompatibility Antigens Class II; Leupeptins; Lysosomes; Primaquine | 1993 |
MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Topics: Acetylcysteine; Animals; Antigen Presentation; Antigen-Presenting Cells; Antigens, Neoplasm; Antimalarials; Brefeldin A; CD4-Positive T-Lymphocytes; Chloroquine; Coculture Techniques; Cysteine Proteinase Inhibitors; Cytosol; Dose-Response Relationship, Drug; Endocytosis; Endoplasmic Reticulum; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Genes, MHC Class II; Humans; Hybridomas; Leupeptins; Major Histocompatibility Complex; Mice; Muramidase; Plasmids; Primaquine; Protein Synthesis Inhibitors; Protein Transport; Ribonucleases; Transfection; Tumor Cells, Cultured | 2000 |